責(zé)任編輯：乳腺癌互助君 封面圖片來源：稿定設(shè)計(jì) 參考來源： [1] Global Cancer Observatory: December, 2020 [2] ALLEMANI C, MATSUDA T, DI CARLO V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125):1023-1075. [3] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials[J]. Lancet, 2015, 386(10001):1341-1352. [4] MAMOUNAS E P, TANG G, PAIK S, et al. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology[J]. Breast Cancer Res Treat, 2018, 168(1):69-77. [5] ALBANELL J, MARTINEZ M T M, RAMOS M, et al. LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase Ⅱ trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor) ＋ / HER2– endocrine sensitive advanced breast cancer (ABC)[J]. Ann Oncol, 2020, 31:S1151. [6] FINN R S, MARTIN M, RUGO H S, et al. Palbociclib and Letrozole in Advanced Breast Cancer[J]. N Engl J Med, 2016, 375(20):1925-1936. [7] TURNER N C, SLAMON D J, RO J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer[J]. N Engl J Med, 2018, 379(20):1926-1936. [8] SLAMON D J, NEVEN P, CHIA S, et al. Phase Ⅲ Randomized Study of Ribociclib and Fulvestrant in Hormone ReceptorPositive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3[J]. J Clin Oncol, 2018, 36(24):2465-2472. [9] TRIPATHY D, IM S A, COLLEONI M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormonereceptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(7):904- 915. [10] YARDLEY D A, NUSCH A, YAP Y S, et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials[J]. J Clin Oncol, 2020, 38(15_suppl):1054. [11] SLEDGE G W J R, TOI M, NEVEN P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial[J]. JAMA Oncol, 2019, 6(1):116-124. [12] NEVEN P, JOHNSTON S R D, TOI M, et al. MONARCH 2: Subgroup analysis of patients receiving abemaciclib ＋ fulvestrant as first- and second-line therapy for HR ＋ , HER2– advanced breast cancer[J]. J Clin Oncol, 2020, 38(15_suppl): 1061. [13] RAZAVI P, CHANG M T, XU G, et al. The Genomic Lands cape of Endocrine-Resistant Advanced Breast Cancers[J]. Cancer Cell, 2018, 34(3):427-438. [14] MOSELE F, STEFANOVSKA B, LUSQUE A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer[J]. Ann Oncol, 2020, 31(3):377-386. [15] ANDRé F, CIRUELOS E, RUBOVSZKY G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer[J]. N Engl J Med, 2019, 380(20):1929-1940. [16] ANDRé F, CIRUELOS E M, JURIC D, et al. LBA18 Overall survival (os) results from SOLAR-1, a phase Ⅲ study of alpelisib (ALP) ＋ fulvestrant (FUL) for hormone receptor-positive (HR ＋ ), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)[J]. Ann Oncol, 2020, 31:S1150-S1151. [17] WANDER S A, JURIC D, SUPKO J G, et al. Phase Ⅰb trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR ＋ )/ HER2 negative metastatic breast cancer (MBC) (TAKTIC)[J]. J Clin Oncol, 2020, 38(15_suppl):1066. [18] SCHMID P, ADAMS S, RUGO H S, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer[J]. N Engl J Med, 2018, 379(22):2108-2121. [19] EMENS L A, ADAMS S, BARRIOS C H, et al. LBA16 IMpassion130: Final OS analysis from the pivotal phase Ⅲ study of atezolizumab ＋ nab-paclitaxel vs placebo ＋ nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer[J]. Ann Oncol, 2020, 31:S1148. [20] MILES D W, GLIGOROV J, ANDRé F, et al. LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase Ⅲ trial of first-line paclitaxel (PAC) ± atezoli zumab (atezo) for unresectable locally advanced/metas tatic triple-negative breast cancer (mTNBC)[J]. Ann Oncol, 2020, 31:S1147-S1148. [21] CORTES J, CESCON D W, RUGO H S, et al. KEYNOTE-355: Randomized, double-blind, phase Ⅲ study of pembrolizumab ＋ chemotherapy versus placebo ＋ chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer[J]. J Clin Oncol, 2020, 38(15_ suppl):1000. [22] WINER E P, LIPATOV O, IM S A, et al. Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119[J]. J Clin Oncol, 2020, 38(15_ suppl):1013. [23] TOLANEY S M, KALINSKY K, KAKLAMANI V G, et al. A phase Ⅰb/Ⅱ study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1)[J]. J Clin Oncol, 2020, 38(15_suppl):1015. 翟婧彤, 呂丹, 馬飛., 2020年度乳腺癌治療新進(jìn)展., 腫瘤綜合治療電子雜志[J], 2021年第1期24-33,共10頁(yè)., 中國(guó)醫(yī)學(xué)科學(xué)院醫(yī)學(xué)與健康科技創(chuàng)新工程協(xié)同創(chuàng)新團(tuán)隊(duì)項(xiàng)目 (2017-I2M-3-004) 2021-06-05 癌細(xì)胞是如何一步步發(fā)生轉(zhuǎn)移的？做好萬全準(zhǔn)備才能戰(zhàn)勝癌癥 2021-06-04 乳腺癌康復(fù)期的四大誤區(qū)，你占了幾個(gè)？ 2021-06-03
聯(lián)系客服
